Maha Eid Alsubaie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maha Eid Alsubaie has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Hussain Almohammed
College of Medicine, King Faisal University, Al Ahsa 31982, Saudi Arabia
2 shared publications - Amara M. Mufti
College of Medicine, Fakeeh College for Medical Sciences, Jeddah 23323, Saudi Arabia
1 shared publication - Feras Alsultan
Department of Neurology, Almoosa Specialist Hospital, Al Ahsa 31982, Saudi Arabia
1 shared publication - Hamad A. Alseni
College of Medicine, King Abdulaziz University, Jeddah 23452, Saudi Arabia
1 shared publication - Hussain Ali Alali
College of Medicine, King Faisal University, Al Ahsa 31982, Saudi Arabia
1 shared publication - Jory H. Alzahrani
College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah 21423, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 19 November 2026
- Published by MDPI AG in Neurology International
- Vol. 18 (11) , 221
Cognitive Changes in Epilepsy: A Narrative Review
Cognitive alterations are a common but under-recognized aspect of epilepsy that can significantly alter patients’ quality of life. Although several reviews have addressed this topic, few have explicitly weighed the strength of the underlying evidence or translated it into a practical approach to assessment. This narrative review therefore aimed to critically synthesize the epidemiological and clinical evidence on cognitive impairment in epilepsy, to grade the evidence supporting key associations and treatment effects, and to propose a practical framework for assessment and management. A structured literature search was performed in PubMed, Web of Science, and the Cochrane Library (including the Cochrane Central Register of Controlled Trials) using a search strategy that is tailored toward epilepsy/seizure disorders, cognitive impairment/cognition, and cognitive domains. Studies that evaluated cognitive changes in patients with epilepsy were included, whereas studies that were not written in English or did not directly address the main objectives were excluded. Cognitive impairment is common in both adults and children with epilepsy, although prevalence estimates depend strongly on how cognition is defined and measured (administrative diagnoses of intellectual disability, domain-specific test deficits, subjective complaints, or longitudinal decline), and the burden is greatest in drug-resistant epilepsy. Evidence, mainly from temporal lobe epilepsy, suggests that impairment across domains reflects disruption of distributed networks rather than damage to one specific region. Longer disease duration, frequent or uncontrolled seizures and drug resistance are consistently associated with poorer cognition, whereas the effect of earlier age at onset appears to depend on clinical context, being most evident in children whose epilepsy becomes pharmacoresistant. Different epilepsy syndromes may present with different patterns of cognitive impairment; for example, memory is predominantly affected in temporal lobe epilepsy, whereas executive dysfunction is particularly prominent in juvenile myoclonic epilepsy. Among antiseizure medications, the most consistent evidence of cognitive harm concerns topiramate and a high total drug load and, largely on the basis of trials in populations without epilepsy, phenobarbital, whereas evidence for most newer agents is limited and predominantly observational and does not establish either cognitive safety or benefit; cognitive outcomes after epilepsy surgery and neuromodulation derive largely from observational cohorts and should not be interpreted causally. Cognitive impairment is a significant and multifactorial aspect of epilepsy that should be considered alongside seizure control, with early recognition, targeted cognitive screening and individualized management potentially helping to preserve cognitive function and improve patients’ quality of life, although evidence that routine screening improves long-term outcomes is still lacking.
- 19 November 2026
- Published by MDPI AG in Neurology International
- Vol. 18 (11) , 221
Open AccessCognitive Changes in Epilepsy: A Narrative Review
Cognitive alterations are a common but under-recognized aspect of epilepsy that can significantly alter patients’ quality of life. Although several reviews have addressed this topic, few have explicitly weighed the strength of the underlying evidence or translated it into a practical approach to assessment. This narrative review therefore aimed to critically synthesize the epidemiological and clinical evidence on cognitive impairment in epilepsy, to grade the evidence supporting key associations and treatment effects, and to propose a practical framework for assessment and management. A structured literature search was performed in PubMed, Web of Science, and the Cochrane Library (including the Cochrane Central Register of Controlled Trials) using a search strategy that is tailored toward epilepsy/seizure disorders, cognitive impairment/cognition, and cognitive domains. Studies that evaluated cognitive changes in patients with epilepsy were included, whereas studies that were not written in English or did not directly address the main objectives were excluded. Cognitive impairment is common in both adults and children with epilepsy, although prevalence estimates depend strongly on how cognition is defined and measured (administrative diagnoses of intellectual disability, domain-specific test deficits, subjective complaints, or longitudinal decline), and the burden is greatest in drug-resistant epilepsy. Evidence, mainly from temporal lobe epilepsy, suggests that impairment across domains reflects disruption of distributed networks rather than damage to one specific region. Longer disease duration, frequent or uncontrolled seizures and drug resistance are consistently associated with poorer cognition, whereas the effect of earlier age at onset appears to depend on clinical context, being most evident in children whose epilepsy becomes pharmacoresistant. Different epilepsy syndromes may present with different patterns of cognitive impairment; for example, memory is predominantly affected in temporal lobe epilepsy, whereas executive dysfunction is particularly prominent in juvenile myoclonic epilepsy. Among antiseizure medications, the most consistent evidence of cognitive harm concerns topiramate and a high total drug load and, largely on the basis of trials in populations without epilepsy, phenobarbital, whereas evidence for most newer agents is limited and predominantly observational and does not establish either cognitive safety or benefit; cognitive outcomes after epilepsy surgery and neuromodulation derive largely from observational cohorts and should not be interpreted causally. Cognitive impairment is a significant and multifactorial aspect of epilepsy that should be considered alongside seizure control, with early recognition, targeted cognitive screening and individualized management potentially helping to preserve cognitive function and improve patients’ quality of life, although evidence that routine screening improves long-term outcomes is still lacking.
- Open Access
Implantable Cardiac Monitoring for Atrial Fibrillation Detection in Patients with Stroke: A Systematic Review and Meta-Analysis
Background: Atrial fibrillation (AF) is a common but frequently undiagnosed cause of ischemic stroke, particularly among patients with cryptogenic stroke and embolic stroke of undetermined source (ESUS). Implantable cardiac monitors (ICMs) enable prolonged continuous rhythm monitoring and may improve AF detection following ischemic stroke or transient ischemic attack (TIA). This systematic review and meta-analysis aimed to evaluate the diagnostic yield, clinical impact, and safety of prolonged ICM monitoring in patients with ischemic stroke or TIA. Methods: This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines and registered with PROSPERO (CRD42024573913). PubMed, Google Scholar, and the Cochrane Library were systematically searched. Randomized controlled trials and observational studies evaluating the use of ICMs after ischemic stroke or TIA were included. Randomized evidence was synthesized narratively, whereas single-arm random-effects meta-analyses of observational studies were performed to estimate pooled proportions for AF detection, oral anticoagulation initiation, recurrent ischemic stroke or TIA, and device-related adverse events. Results: Twelve completed studies involving 4563 participants met the inclusion criteria, including two randomized controlled trials and ten observational studies. One additional ongoing randomized controlled trial (Find-AF 2) involving a planned enrollment of 5200 participants was identified and is described narratively. Across the observational studies, the pooled AF detection rate during prolonged ICM monitoring was 25.9% (95% CI, 18.9–33.5%), although substantial heterogeneity was observed (I2 = 95%). Oral anticoagulation was initiated in 94.2% (95% CI, 79.4–100.0%) of patients diagnosed with AF. Device-related complications were uncommon, with a pooled incidence of 3.7% (95% CI, 2.0–6.0%; I2 = 0%), while the pooled rate of recurrent ischemic stroke or TIA during follow-up was 6.2% (95% CI, 3.9–9.2%). Narrative synthesis of the randomized evidence demonstrated that ICMs significantly increased AF detection compared with conventional monitoring but did not demonstrate a significant reduction in recurrent stroke during the available follow-up period. Conclusions: Prolonged implantable cardiac monitoring identifies AF in approximately one-quarter of patients following ischemic stroke or TIA and frequently leads to the initiation of oral anticoagulation, with a favorable safety profile. Although ICMs substantially improve AF detection, current evidence remains insufficient to confirm that increased detection translates into a reduction in recurrent stroke. Large, adequately powered randomized controlled trials are needed to determine the long-term clinical benefits of ICM-guided management and to define the optimal monitoring strategy for patients following ischemic stroke.
Open AccessImplantable Cardiac Monitoring for Atrial Fibrillation Detection in Patients with Stroke: A Systematic Review and Meta-Analysis
Background: Atrial fibrillation (AF) is a common but frequently undiagnosed cause of ischemic stroke, particularly among patients with cryptogenic stroke and embolic stroke of undetermined source (ESUS). Implantable cardiac monitors (ICMs) enable prolonged continuous rhythm monitoring and may improve AF detection following ischemic stroke or transient ischemic attack (TIA). This systematic review and meta-analysis aimed to evaluate the diagnostic yield, clinical impact, and safety of prolonged ICM monitoring in patients with ischemic stroke or TIA. Methods: This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines and registered with PROSPERO (CRD42024573913). PubMed, Google Scholar, and the Cochrane Library were systematically searched. Randomized controlled trials and observational studies evaluating the use of ICMs after ischemic stroke or TIA were included. Randomized evidence was synthesized narratively, whereas single-arm random-effects meta-analyses of observational studies were performed to estimate pooled proportions for AF detection, oral anticoagulation initiation, recurrent ischemic stroke or TIA, and device-related adverse events. Results: Twelve completed studies involving 4563 participants met the inclusion criteria, including two randomized controlled trials and ten observational studies. One additional ongoing randomized controlled trial (Find-AF 2) involving a planned enrollment of 5200 participants was identified and is described narratively. Across the observational studies, the pooled AF detection rate during prolonged ICM monitoring was 25.9% (95% CI, 18.9–33.5%), although substantial heterogeneity was observed (I2 = 95%). Oral anticoagulation was initiated in 94.2% (95% CI, 79.4–100.0%) of patients diagnosed with AF. Device-related complications were uncommon, with a pooled incidence of 3.7% (95% CI, 2.0–6.0%; I2 = 0%), while the pooled rate of recurrent ischemic stroke or TIA during follow-up was 6.2% (95% CI, 3.9–9.2%). Narrative synthesis of the randomized evidence demonstrated that ICMs significantly increased AF detection compared with conventional monitoring but did not demonstrate a significant reduction in recurrent stroke during the available follow-up period. Conclusions: Prolonged implantable cardiac monitoring identifies AF in approximately one-quarter of patients following ischemic stroke or TIA and frequently leads to the initiation of oral anticoagulation, with a favorable safety profile. Although ICMs substantially improve AF detection, current evidence remains insufficient to confirm that increased detection translates into a reduction in recurrent stroke. Large, adequately powered randomized controlled trials are needed to determine the long-term clinical benefits of ICM-guided management and to define the optimal monitoring strategy for patients following ischemic stroke.